v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Cash flows from operating activities:      
Net loss $ (153,040) $ (305,250) $ (48,359)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:      
Depreciation and amortization 97,344 102,093 96,576
Non-cash interest 4,903 2,575 2,699
Amortization of deferred financing costs 187 224 237
Losses from investments in investees 14,497 14,471 7,652
Equity-based compensation – employees and non-employees 21,761 28,307 42,693
Asset impairment charges 21,778 13,194 0
Realized loss (gain) on disposal of fixed assets and sales of equity securities 46 (8,663) 2,321
Loss (gain) on conversion of 3.00% convertible senior notes 0 0 284
Change in fair value of equity securities and derivative instruments (6,524) (52) (2,778)
Change in fair value of contingent consideration (16,816) (3,423) 16,954
Deferred income tax provision (benefit) (35,133) 16,092 (66,300)
Changes in assets and liabilities, net of the effects of acquisitions:      
Accounts receivable, net 20,397 58,011 (25,637)
Inventory, net 4,590 (3,539) (6,607)
Other current assets and prepaid expenses 2,276 4,771 17,262
Other assets (69) (2,372) (1,899)
Accounts payable (26,083) 20,171 (19,819)
Foreign currency measurement 294 (255) (376)
Contract liabilities (61,264) (58,876) (50,893)
Accrued expenses and other liabilities 1,715 30,441 68,036
Net cash (used in) provided by operating activities (109,141) (92,080) 32,046
Cash flows from investing activities:      
Investments in investees (1,000) (9,625) (14,424)
Proceeds from sale of equity securities 1,516 2,211 0
Acquisition of businesses, net of cash acquired 0 0 15,878
Acquisition of intangible assets 0 0 (5,000)
Purchase of marketable securities 0 0 (15,644)
Maturities of short-term marketable securities 0 0 15,634
Proceeds from the sale of property, plant and equipment 1,223 7,271 1,401
Capital expenditures (27,858) (46,524) (18,547)
Net cash used in investing activities (26,119) (46,667) (20,702)
Cash flows from financing activities:      
Issuance of common stock 92,500 0 0
Issuance of 2023 Convertible Notes, including to related parties 55,000 0 0
Proceeds from the exercise of Common Stock options and warrants 1,173 2,132 8,576
Borrowings on lines of credit 26,917 92,421 22,407
Repayments of lines of credit (34,681) (33,510) (66,178)
Net cash provided by (used in) financing activities 140,909 61,043 (35,195)
Effect of exchange rate changes on cash and cash equivalents (675) 470 (1,014)
Net increase (decrease) in cash and cash equivalents 4,974 (77,234) (24,865)
Cash and cash equivalents at beginning of period 91,499 168,733 193,598
Cash and cash equivalents at end of period 96,473 91,499 168,733
SUPPLEMENTAL INFORMATION:      
Interest paid 2,076 1,313 2,890
Income taxes paid, net of refunds (1,410) 5,416 (27,122)
Non-cash financing:      
Shares issued upon the conversion of - Common Stock options and warrants, surrendered in net exercise 806 1,546 350
Transition Therapeutics, Inc.      
Issuance of capital stock to acquire or contingent consideration settlement:      
Capital stock issued 0 0 58,530
OPKO Renal      
Issuance of capital stock to acquire or contingent consideration settlement:      
Capital stock issued 0 0 25,986
OPKO Health Europe      
Issuance of capital stock to acquire or contingent consideration settlement:      
Capital stock issued 0 304 313
Issuance of stock for investment in Xenetic      
Issuance of capital stock to acquire or contingent consideration settlement:      
Capital stock issued 0 0 4,856
2033 Senior Notes      
Non-cash financing:      
Shares issued upon the conversion of - 2033 Senior Notes $ 0 $ 0 $ 583

Source